Pipeline

ABL111

HomePipelineABL111

  • Pipeline
    ABL111
  • Program Target
    Claudin18.2x4-1BB
  • Disease Indication
    Solid Tumor
  • Development Stage
    Clinical Development
    (Phase 1)
Summary
ABL111 is a bispecific antibody that targets Claudin18.2, a tumor antigen overexpressed in gastric- and pancreatic-specific cancer, and 4-1BB, a co-stimulatory receptor with the ability to induce potent anti-tumor activity. To minimize the usual toxicity associated with monospecific 4-1BB based treatments, ABL111 only activates the 4-1BB pathway when engaged with Claudin 18.2, thus triggering T cell activation and enhancing anti-tumor immunity while minimizing toxicity. ABL111 shows superior anti-tumor activity in an animal model system compared to Claudin18.2 alone, 4-1BB alone, and the combination of both Claudin18.2 and 4-1BB, with immunological memory resistant to any possible recurrence of the cancer cells.

Structure and Mechanism of Action

Structure and Mechanism of Action
좌우스크롤 Structure and Mechanism of Action

Claudin18.2 Dependent 4-1BB Activation

Claudin18.2 Dependent 4-1BB Activation
Claudin18.2 Dependent 4-1BB Activation

Superior Anti-Tumor Effect with Immunological Memory

Superior Anti-Tumor Effect with Immunological Memory
좌우스크롤 Superior Anti-Tumor Effect with Immunological Memory

Increase of effector memory CD8+ T cells and soluble 4-1BB

Increase of effector memory CD8+ T cells and soluble 4-1BB
Increase of effector memory CD8+ T cells and soluble 4-1BB

Posters

좌우스크롤
Posters(Pipeline, Name, Title, PDF)
Pipeline Name Title PDF
ABL111 SITC TJ-CD4B (ABL111), a Claudin18.2-targeted 4-1BB tumor engager induces potent tumordependent immune response without dose-limiting toxicity in preclinical studies PDF 아이콘
AACR 2020 Claudin 18.2 x 4-1BB bispecific antibody induced potent tumor inhibition through tumor-specific 4-1BB activation PDF 아이콘